The sleep tech devices market size is projected to be USD 29.58 billion in 2025, USD 34.74 billion in 2026, and reach USD 79.88 billion by 2031, growing at a CAGR of 18.12% from 2026 to 2031. This report is Segmented by Product Type (Wearables and Non-Wearables), Application (Insomnia, Obstructive Sleep Apnea, and More), End User (Hospitals, and More), Distribution Channel (Online E-Commerce & D2C, and Offline Retail & Specialty Stores), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).
Non-wearables cater to consumers who prefer passive or environmentally friendly interventions. Eight Sleep’s Pod 4 Ultra delivers 32% gains in self-reported sleep quality via dual-zone thermal control. Sleep Number’s Climate360 integrates responsive air chambers at price points beyond USD 10,000, catering to affluent wellness adopters. ResMed’s NightOwl disposable test democratizes diagnostics at USD 149, capturing users who avoid lab studies. The Withings Sleep Mat offers under-mattress sensing but lacks multi-sensor fidelity, which limits its clinical use.
Insomnia accounted for 42.45% of application revenue in 2025, as cognitive behavioral therapy modules embedded in wearables gained traction. Apple’s breathing-exercise sequences reduced sleep-onset latency by 12 minutes in trials, highlighting the convergence of mental health. CPAP and related sleep-apnea devices target a diagnosed base of 936 million, yet most cases remain untreated, leaving a vast diagnostic pool. ResMed’s AirSense 11 utilizes adaptive algorithms that reduce abandonment by 18% compared to fixed-pressure systems.
Narcolepsy devices are advancing at a 20.55% CAGR, the fastest-growing segment, driven by FDA approvals that now include pediatric patients aged six and above. LUMRYZ extended-release sodium oxybate gained clearance in September 2024, with wearables offering objective adherence metrics. Restless-leg monitoring through accelerometers generates an ancillary revenue stream as limb-movement data are validated for clinical decision-making. As real-time data becomes accessible, treatment can shift from episodic office visits to continuous titration.
The Asia-Pacific region records the fastest trajectory, with a 19.43% CAGR. China’s sleep tech devices market surpassed USD 1.2 billion in 2024, driven by e-commerce penetration exceeding 50% and the government's emphasis on preventive health. India’s market, estimated at USD 300 million in 2024, benefits from a shift to local manufacturing that lowers average retail prices. Xiaomi’s Mi Band 8 Pro, selling for USD 50, democratizes tracking for cost-sensitive buyers. Huawei captured a 15% share of China’s wearables segment by integrating TruSleep algorithms into the Watch GT 4.
Europe’s growth lags due to GDPR compliance costs and country-specific reimbursement hurdles. NICE guidance in the United Kingdom approved six home tests priced well below lab studies, signaling payer openness to lower-cost diagnostics. Germany’s statutory insurance now funds CE-marked wearables for insomnia, provided there is evidence of equivalence to CBT-I. The Middle East and Africa, while smaller, are expanding in double digits as Gulf states invest in digital health strategies. South America’s adoption trails because average device prices equal more than 20% of monthly household income, restricting uptake to affluent urban users.
Global Sleep Tech Devices Market Trends and Insights
Increasing Prevalence of Sleep Disorders
An estimated 852 million adults reported experiencing insomnia symptoms in 2024, representing 16.2% of the global adult population. Obstructive sleep apnea diagnoses reached 936 million, yet 80% remain undiagnosed because clinic capacity cannot meet demand. In the United States, 36% of adults disclosed a diagnosed sleep disorder in 2024, underscoring a care gap that home testing can fill. FDA approval of Wakix for pediatric narcolepsy broadened the treated population, elevating demand for monitoring wearables in younger cohorts. Aging populations and rising obesity rates, notably in India and China, further intensify the worldwide incidence of sleep-disordered breathing.Technological Advancements in Wearables, Sensors & AI
The Oura Ring Generation 4 reduced motion artifacts by 30% compared to its earlier model and introduced Advisor AI for personalized coaching. The Apple Watch Series 10 detects sleep apnea with a sensitivity above 85% using accelerometer and heart rate data. SleepViT’s ultra-low-power ASIC executes sleep-stage classification locally, minimizing latency and cloud fees. Samsung Galaxy Watch7 raised sleep-stage concordance to 78%, narrowing the gap with clinical actigraphy. These improvements narrow the performance gap between consumer wearables and lab-grade devices, fostering physician endorsement and insurance reimbursement.High Cost of Advanced Sleep Tech Devices
Eight Sleep’s Pod 4 Ultra retails for between USD 2,000 and USD 3,000, positioning it as a luxury purchase rather than a mass-market health tool. Sleep Number’s Climate360 bed ranges from USD 10,000 to USD 13,500, which limits its uptake to households in the highest income decile. The Oura Ring costs between USD 299 and USD 399 and requires a monthly subscription of USD 5.99 for premium analytics, which raises the total first-year ownership cost above USD 370. CPAP therapy can exceed USD 3,000 when diagnostic polysomnography is needed, delaying initiation for uninsured users. Subscription models heighten affordability concerns, especially in markets where the annual per-capita healthcare expenditure is below USD 200.Other drivers and restraints analyzed in the detailed report include:
- Growing Adoption of Smart-Home Ecosystems for Sleep Optimization
- Regulatory Support for Home Sleep Testing & Reimbursement Expansion
- Data Privacy and Security Concerns
Segment Analysis
Wearables accounted for 65.43% of 2025 revenue, with the segment on track to grow at 20.43% through 2031, as edge analytics and large installed bases reinforce network effects. Oura generated USD 500 million in revenue in 2024 and converted more than 30% of owners into monthly subscribers, a model that lifts margins beyond hardware sales. Apple Watch Series 10 capitalizes on over 200 million active devices, transforming existing users into sleep-apnea patients without incremental bill-of-materials costs. The Samsung Galaxy Watch7 improved sleep-stage accuracy by 12 percentage points over the prior model, bringing the device closer to clinical relevance.Non-wearables cater to consumers who prefer passive or environmentally friendly interventions. Eight Sleep’s Pod 4 Ultra delivers 32% gains in self-reported sleep quality via dual-zone thermal control. Sleep Number’s Climate360 integrates responsive air chambers at price points beyond USD 10,000, catering to affluent wellness adopters. ResMed’s NightOwl disposable test democratizes diagnostics at USD 149, capturing users who avoid lab studies. The Withings Sleep Mat offers under-mattress sensing but lacks multi-sensor fidelity, which limits its clinical use.
Insomnia accounted for 42.45% of application revenue in 2025, as cognitive behavioral therapy modules embedded in wearables gained traction. Apple’s breathing-exercise sequences reduced sleep-onset latency by 12 minutes in trials, highlighting the convergence of mental health. CPAP and related sleep-apnea devices target a diagnosed base of 936 million, yet most cases remain untreated, leaving a vast diagnostic pool. ResMed’s AirSense 11 utilizes adaptive algorithms that reduce abandonment by 18% compared to fixed-pressure systems.
Narcolepsy devices are advancing at a 20.55% CAGR, the fastest-growing segment, driven by FDA approvals that now include pediatric patients aged six and above. LUMRYZ extended-release sodium oxybate gained clearance in September 2024, with wearables offering objective adherence metrics. Restless-leg monitoring through accelerometers generates an ancillary revenue stream as limb-movement data are validated for clinical decision-making. As real-time data becomes accessible, treatment can shift from episodic office visits to continuous titration.
Complete Report Scope:
- By Product Type
- Wearables
- Smart Watches & Bands
- Smart Rings
- Other Wearable Devices
- Non-Wearables
- Sleep Monitors (Under-Mattress / Bedside)
- Smart Beds & Mattresses
- Other Non-Wearable Devices
- Wearables
- By Application
- Insomnia
- Obstructive Sleep Apnea
- Narcolepsy
- Restless Leg Syndrome & Other Disorders
- By End User
- Hospitals
- Sleep Labs & Clinics
- Homecare Settings
- Wellness Centers & Corporate Programs
- By Distribution Channel
- Online (E-Commerce & D2C)
- Offline Retail & Specialty Stores
- Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest Of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest Of Asia-Pacific
- Middle East And Africa
- GCC
- South Africa
- Rest Of Middle East And Africa
- South America
- Brazil
- Argentina
- GCC
- Rest Of South America
- Turkey
- North America
Geography Analysis
North America retained 42.87% of revenue in 2025 as high insurance coverage and early FDA clearances fostered adoption. ResMed generated USD 2.3 billion in 2024 Americas revenue, reflecting robust CPAP uptake and growth in cloud subscriptions. Canada expanded provincial reimbursement for home testing, extending access beyond urban sleep labs.The Asia-Pacific region records the fastest trajectory, with a 19.43% CAGR. China’s sleep tech devices market surpassed USD 1.2 billion in 2024, driven by e-commerce penetration exceeding 50% and the government's emphasis on preventive health. India’s market, estimated at USD 300 million in 2024, benefits from a shift to local manufacturing that lowers average retail prices. Xiaomi’s Mi Band 8 Pro, selling for USD 50, democratizes tracking for cost-sensitive buyers. Huawei captured a 15% share of China’s wearables segment by integrating TruSleep algorithms into the Watch GT 4.
Europe’s growth lags due to GDPR compliance costs and country-specific reimbursement hurdles. NICE guidance in the United Kingdom approved six home tests priced well below lab studies, signaling payer openness to lower-cost diagnostics. Germany’s statutory insurance now funds CE-marked wearables for insomnia, provided there is evidence of equivalence to CBT-I. The Middle East and Africa, while smaller, are expanding in double digits as Gulf states invest in digital health strategies. South America’s adoption trails because average device prices equal more than 20% of monthly household income, restricting uptake to affluent urban users.
List of Companies Covered in this Report:
- Apple
- Casper Sleep Inc.
- Compumedics
- Dreem SAS
- Eight Sleep
- Fitbit (Google LLC)
- Garmin
- Huawei Technologies Co. Ltd.
- Koninklijke Philips
- Nihon Kohden
- Oura Health Oy
- Resmed
- Samsung Group
- Sleep Number Corporation
- Sleepace
- Withings SA
- Xiaomi Corporation
- Zepp Health Corp.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size & Growth Forecasts (Value, USD)
6 Competitive Landscape
7 Market Opportunities & Future Outlook
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Apple Inc.
- Casper Sleep Inc.
- Compumedics Limited
- Dreem SAS
- Eight Sleep
- Fitbit (Google LLC)
- Garmin Ltd.
- Huawei Technologies Co. Ltd.
- Koninklijke Philips N.V.
- Nihon Kohden Corporation
- Oura Health Oy
- ResMed Inc.
- Samsung Electronics Co. Ltd.
- Sleep Number Corporation
- Sleepace
- Withings SA
- Xiaomi Corporation
- Zepp Health Corp.
